Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.

Nivolumab/Ipilimumab Combination Active in Recurrent SCLC

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC

Dr. Madhav Dhodapkar on IMiD-based Combinations in Multiple Myeloma

A Look Ahead in Genitourinary Cancers

The Role of Biomarkers in Bladder Cancer

Measuring Response in Non-Muscle Invasive Bladder Cancer

Approaches in High-Risk Non-Muscle Invasive Bladder Cancer

Check Point Inhibition in Muscle-Invasive Bladder Cancer

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer

First-Line Options in Muscle-Invasive Bladder Cancer

Abiraterone Plus Prednisone in CRPC: Factors to Consider

CRPC: Patient Selection in AR-Directed Therapies

Therapeutic Options in Metastatic CRPC

Safety of Low-Dose Steroids with Abiraterone in Prostate Cancer

Potential Predictive Markers in Prostate Cancer

Candidacy for Chemotherapy in Oligometastatic Prostate Cancer

Local and Systemic Therapeutic Options in Low-Volume Prostate Cancer

Combining Radium-223 With Other Therapies in Prostate Cancer

Factors Impacting Treatment Approach in Advanced Prostate Cancer

Defining Symptomatic in Prostate Cancer

Immuno-Oncology

Immuno-Oncology | Specialty